If Paper Cuts Could Kill: The World Health Organization Launches its Antimicrobial Resistance Campaign

By Thanusha Pillay

May 21, 2024

Introduction:

In 1928, Alexander Fleming discovered penicillin, the first antibiotic. Since then, antimicrobials have completely shifted healthcare, saving countless lives that would have otherwise been lost to anything from the tiniest scrape to an otherwise safe childbirth. However, the rise of antimicrobial resistance (AMR) threatens this progress, rendering once-effective treatments ineffective. AMR presents a global crisis, impacting health, economies, and livelihoods worldwide – yet many people aren’t even aware this threat exists.

The Silent Threat of AMR:

The resistance of microbes – bacteria, viruses, fungi, and parasites – poses a grave challenge. When these microorganisms no longer respond to treatments, infections become difficult to treat or untreatable, elevating the risk of severe illness and mortality. The toll is staggering, with 1.3 million deaths directly attributed to AMR annually, and a further 5 million AMR-related deaths. AMR also threatens future livelihoods, with an estimated annual cost of US$3.4 trillion by 2030 and 28 million people becoming poverty-stricken by 2050.

Human Cost of AMR:

Beyond statistics lies real people and their families. AMR leads to limited treatment options, prolonged hospital stays, financial strain, and emotional turmoil. The impact is indiscriminate, affecting individuals regardless of health status, with even minor ailments posing life-threatening risks. Clinically vulnerable individuals such as those with cancer, diabetes, or HIV, risk facing a dangerous infection that their bodies have little chance of overcoming without an effective treatment.

A Global Menace:

AMR transcends borders, posing a dual threat to public health and food security. Straining healthcare systems, AMR undermines treatment efficacy, prolonging illnesses and inflating healthcare costs. Moreover, the spread of AMR through the food chain jeopardises both animal and human health, crippling agricultural economies worldwide.

Voices Against AMR:

In a bid to spur action, the WHO has launched their AMR Awareness Campaign and called upon 12 survivors and advocates to share their poignant experiences with AMR. This emphasises the urgent need for intervention to combat this silent adversary. Last year, the WHO also published a global research agenda for antimicrobial resistance in human health, prioritising evidence generation for 40 research topics that will inform policy by 2030.

Unity in the Face of Adversity:

Much like the response to COVID-19, addressing drug-resistant infections demands a united front. AMR respects no boundaries, necessitating collaborative efforts on a global scale. The battle against AMR is a collective responsibility, requiring coordinated action to safeguard public health, food security, and sustainable development goals.

Call to Action:

Join the fight against AMR. Together, we can preserve the efficacy of antimicrobial medicines, protect lives, and secure a healthier future for all. Raise awareness, advocate for responsible antimicrobial use, and support initiatives aimed at combating this pressing global threat.

Reference url

Recent Posts

Impact of Insulin Copay Caps on Medicare Beneficiary Health and Spending

By João L. Carapinha

April 7, 2026

In this update, we highlight a JAMA Internal Medicine article that analyzed the real-world impact of insulin copay caps on Medicare beneficiaries with type 2 diabetes. According to a new study, these policies have successfully lowered out-of-pocket insulin costs and improved adherence among exist...
100% Tariffs Impacting Pharmaceutical Manufacturing and National Security

By João L. Carapinha

April 3, 2026

President Donald J. Trump has imposed tariffs on patented pharmaceutical products and their ingredients, using tariffs pharmaceutical manufacturing policy to protect national security and strengthen U.S. supply chains. The move applies a baseline 100% tariff on patented pharmaceuticals, with lowe...
Enhancing Obesity Treatment Pricing in South Africa Through Competitive Strategies

By João L. Carapinha

April 2, 2026

Novo Nordisk has cut the price of Wegovy for the second time in South Africa, making obesity treatment pricing South Africa a key focus for improved patient access. The latest reductions, announced on 25 March 2026, lower the lowest injectable dose from 3,090 rand to 1,873 rand and the highest do...